RNF168 (Ring Finger Protein 168)

To translate this mechanism, we engineered an injectable hydrogel for the sequential co-delivery of cisplatin and PRMT6/USP7 inhibitors, demonstrating significantly enhanced therapeutic efficacy. Our study unveils a previously unrecognized bifunctional role for the PRMT6-USP7 axis in orchestrating epigenetic reprogramming and DNA repair to confer platinum resistance, providing profound mechanistic insights and a compelling co-targeting strategy for overcoming chemoresistance in breast cancer.

Collectively, our study identifies a feedback regulatory loop between SOX12 and RNF168 that promotes DNA damage repair and cisplatin resistance in esophageal cancer cells.

Regulation of the TRIM39-RNF168 axis, achieved by knocking down TRIM39 or RNF168, can activate autophagy-coupled ferroptosis in TNBC cells. The activated autophagy-ferroptosis pathway effectively suppresses TNBC progression in vivo, presenting a promising potential therapeutic approach.

Depletion of RAD18, fork remodelers, or the endonuclease MUS81 rescues these phenotypes, indicating that mH2A1.2-ubiquitination prevents toxic RAD18 engagement at MUS81-dependent double-strand breaks (DSBs), which arise at collapsed forks in difficult-to-replicate sites experiencing prolonged arrest. Our findings highlight the detrimental consequences of inappropriate DNA processing by MUS81 at these loci.

Notably, SQSTM1/p62-knockout significantly attenuated SiNPs-induced DNA damage and malignant transformation , and modulated the expression of Aurora B and RNF168 signaling pathways. These findings demonstrated the critical role of SQSTM1/p62-mediated autophagy dysfunction in SiNPs-induced genotoxicity and malignant transformation in lungs, offering novel insights into SiNPs-related carcinogenicity.

Whereas, varying expression levels of ZNF451 and RNF8 suggest that both facilitate the interaction between RNF168 and the downstream factor H2AX, but the interaction plateaus beyond a specific threshold. Altogether, these findings reveal that the SUMOylation catalyzed by ZNF451 is involved in regulating RNF168-induced ubiquitin signaling in DSBs repair and suggest that ZNF451 could serve as a potential therapeutic target in tumor radiotherapy.

Dysregulation of the precisely coordinated network of H2AK13/15ub is strongly associated with various diseases, including RIDDLE syndrome, neurodegenerative disorders, immune deficiencies, and breast cancer. This review systematically analyzes the dynamic regulation of H2AK13/15ub in DDR and explores its therapeutic potential for disease intervention.

In silico analysis of FDA-approved drugs led to the identification of an ACE inhibitor, ramipril, that protected against sunitinib-induced vascular dysfunction in vitro and in vivo, all while preserving the efficacy of cancer therapy. Our study established a central role for translational control of SND1 in sunitinib-induced endothelial dysfunction that could potentially be therapeutically targeted to reduce sunitinib-induced vascular toxicity.

Mechanistically, LOC730101 specifically binds to BECN1 and inhibits the formation of autophagosome BECN1/VPS34 by reducing phosphorylation of BECN1, thereby inhibiting autophagy and promoting drug sensitivity in ovarian cancer cells following treatment with cisplatin and PARP inhibitors...Our findings demonstrated that LOC730101 played an important role in regulating the formation of the autophagic complex and that inhibition of autophagy significantly enhances the drug sensitivity of OC. And LOC730101 may be used as a prognostic marker to predict the sensitivity of OC to platinum and PARP inhibitors.

Additionally, the procedure developed based on expression levels of TMEM182, MCM9, LRRFIP1, LAMP1, FAM161A, KLHL36, ETV5, RNF168, SRSF11, NCKAP5, CRTAP, VAMP2, ZBTB49 and RIMBP2 proved to be capable in predicting FOLFOX therapy response. In conclusion, our approach can give a unique insight into clinical decision-making regarding therapy scheme administration, potentially increasing patients' survival and, consequently, medical futility due to incorrect therapy application.

Furthermore, the HECTD3/UbcH5b inhibitor, PC3-15, increased the radiosensitivity of TNBC cells by inhibiting DNA damage repair. Taken together, we conclude that HECTD3 promotes autophagy and DNA damage repair in response to irradiation in a p62-denpendent manner, and that inhibition of the HECTD3-p62 axis could be a potential therapeutic strategy for patients with TNBC in addition to radiotherapy.

Together, our results support the hypothesis of poly-ubiquitylated H1 guiding RNF168 recruitment to DSB sites. Moreover, we demonstrate how the streamlined synthesis of H1KxUb2 variants enables mechanistic studies into RNF168 regulation, with potential implications for its inhibition in susceptible cancers.